---
schema_version: "secwatch.filing_event.v1"
accession: "0001724521-24-000034"
form_type: "8-K"
ticker: "RCUS"
cik: "0001724521"
company_name: "Arcus Biosciences, Inc."
filed_at: "2024-01-30T23:59:59+00:00"
generated_at: "2026-06-06T15:05:35.119483+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Gilead invests $320M in Arcus at $21/share; collaboration amended to accelerate anti-TIGIT program

## Summary
- Gilead purchases 15.2M shares for $320M at $21/share, increasing ownership to 33%.
- Collaboration reprioritized: focus on Phase 3 STAR-121 (lung) and STAR-221 (GI); ARC-10 discontinued.
- New Phase 3 STAR-131 registrational study for domvanalimab + zimberelimab in lung cancer planned.
- Johanna Mercier (Gilead CCO) appointed to Arcus board; two prior Gilead designees resign.
- Quemliclustat pancreatic cancer study becomes Arcus-independent; cash runway extended into 2027.

## SEC filing metadata
- accession: 0001724521-24-000034
- form_type: 8-K
- ticker: RCUS
- cik: 0001724521
- company_name: Arcus Biosciences, Inc.
- filed_at: 2024-01-30T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 1.01, 3.02, 5.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1724521/000172452124000034/0001724521-24-000034-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1724521/000172452124000034/rcus-20240129.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001724521-24-000034
- JSON: https://secwatch.observer/filing/0001724521-24-000034.json
- Plain text: https://secwatch.observer/filing/0001724521-24-000034.txt

## Key facts
- Executive change
  Johanna Mercier was appointed as Class II Director at Arcus Biosciences, Inc..
  - Action: appointed
  - Role: Class II Director
  source text: the Board appointed Johanna Mercier to the Board as a Class II director
  evidence_url: https://www.sec.gov/Archives/edgar/data/1724521/000172452124000034/0001724521-24-000034-index.htm
- Executive change
  Ms. Jarrett resigned as Director at Arcus Biosciences, Inc..
  - Action: resigned
  - Role: Director
  source text: Dr. Jaen and Ms. Jarrett resigned from the Board
  evidence_url: https://www.sec.gov/Archives/edgar/data/1724521/000172452124000034/0001724521-24-000034-index.htm
- Executive change
  Dr. Jaen resigned as Director at Arcus Biosciences, Inc..
  - Action: resigned
  - Role: Director
  source text: Dr. Jaen and Ms. Jarrett resigned from the Board
  evidence_url: https://www.sec.gov/Archives/edgar/data/1724521/000172452124000034/0001724521-24-000034-index.htm
- Material Agreements
  Arcus Biosciences, Inc. entered into Third Amended and Restated Common Stock Purchase Agreement with Gilead Sciences, Inc. (effective 2024-01-29).
  - Action: entry
  - Agreement: equity purchase
  - Counterparty: Gilead Sciences, Inc.
  - Effective: 2024-01-29
  source text: On January 29, 2024, Arcus Biosciences, Inc. (the “Company”) and Gilead Sciences, Inc. (“Gilead”) entered into a Third Amended and Restated Common Stock Purchase Agreement (the “A&R Purchase Agreement”), which amends and restates in its entirety the Second Amended & Restated Common Stock Purchase Agreement dated June 27, 2023 (the “Existing Purchase Agreement”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1724521/000172452124000034/0001724521-24-000034-index.htm
- Material Agreements
  Arcus Biosciences, Inc. amended Amendment No. 3 with Gilead Sciences, Inc. (effective 2024-01-29).
  - Action: amendment
  - Agreement: license
  - Counterparty: Gilead Sciences, Inc.
  - Effective: 2024-01-29
  source text: On January 29, 2024, the Company and Gilead also entered into Amendment No. 3 (“Amendment No. 3”) to the Option, License and Collaboration Agreement, dated May 27, 2020, as amended on November 17, 2021 and May 12, 2023 (as previously amended, the “OLCA”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1724521/000172452124000034/0001724521-24-000034-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.